Modulation of Bitter Taste Perception by a Small Molecule hTAS2R Antagonist  by Slack, Jay P. et al.
Modulation of Bitter Taste PCurrent Biology 20, 1104–1109, June 22, 2010 ª2010 Elsevier Ltd All rights reserved DOI 10.1016/j.cub.2010.04.043Report
erception
by a Small Molecule hTAS2R AntagonistJay P. Slack,1,* Anne Brockhoff,2 Claudia Batram,2
Susann Menzel,2 Caroline Sonnabend,2 Stephan Born,2
Maria Mercedes Galindo,2 Susann Kohl,2 Sophie Thalmann,2
Liliana Ostopovici-Halip,4 Christopher T. Simons,1
Ioana Ungureanu,1 Kees Duineveld,5 Cristian G. Bologa,3
Maik Behrens,2 Stefan Furrer,1 Tudor I. Oprea,3
and Wolfgang Meyerhof2,*
1Givaudan Flavors Corporation, 1199 Edison Drive, Cincinnati,
OH 45216, USA
2Department of Molecular Genetics, German Institute
of Human Nutrition Potsdam-Rehbruecke,
Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany
3Division of Biocomputing, Department of Biochemistry and
Molecular Biology, University of New Mexico School
of Medicine, Albuquerque, NM 87131, USA
4Institute of Chemistry, Romanian Academy,
Timisoara 300223, Romania
5Givaudan Nederland BV, Huizerstraatweg 28,
1411 GP Naarden, Netherlands
Summary
Human bitter taste is mediated by the hTAS2R family of G pro-
tein-coupled receptors [1–4]. The discovery of the hTAS2Rs
enables the potential to develop specific bitter receptor antag-
onists that could be beneficial as chemical probes to examine
the role of bitter receptor function in gustatory and nongusta-
tory tissues. In addition, they could have widespread utility in
food and beverages fortified with vitamins, antioxidants, and
other nutraceuticals, because many of these have unwanted
bitter aftertastes. We employed a high-throughput screen-
ing approach to discover a novel bitter receptor antagonist
(GIV3727) that inhibits activation of hTAS2R31 (formerly
hTAS2R44) by saccharin and acesulfame K, two common arti-
ficial sweeteners. Pharmacological analyses revealed that
GIV3727 likely acts as an orthosteric, insurmountable antago-
nist of hTAS2R31. Surprisingly, we also found that this com-
pound could inhibit five additional hTAS2Rs, including the
closely related receptor hTAS2R43. Molecular modeling and
site-directed mutagenesis studies suggest that two residues
in helix 7 are important for antagonist activity in hTAS2R31
and hTAS2R43. In human sensory trials, GIV3727 significantly
reduced the bitterness associated with the two sulfonamide
sweeteners, indicating that hTAS2R antagonists are active
in vivo. Our results demonstrate that small molecule bitter
receptor antagonists can effectively reduce the bitter taste
qualities of foods, beverages, and pharmaceuticals.
Results and Discussion
Identification and Characterization of a Small Molecule
Bitter Receptor Antagonist
To identify putative antagonists of the human hTAS2R31 bitter
receptor, we constructed a double stable cell line expressing*Correspondence: jay.slack@givaudan.com (J.P.S.), meyerhof@dife.de
(W.M.)hTAS2R31 along with the chimeric G protein G16gust44 in
HEK293 cells. This cell line was used for high-throughput
biomolecular screening via calcium imaging. After thorough
data analysis of the screening set (17,854 compounds total)
and hit selection, we identified 139 candidate antagonists.
One compound in particular, GIV3727 (4-(2,2,3-trimethylcyclo-
pentyl)butanoic acid), was selected as a robust inhibitor of
hTAS2R31 (Figure 1A). Potency assessments in hTAS2R31-
expressing cells revealed that the half-maximal inhibitory
concentration (IC50) of GIV3727 for both agonists was 6.4 6
2.4 mM (n = 3) for acesulfame K and 7.9 6 6.1 mM (n = 3) for
saccharin (Figure 1B). Inhibition of hTAS2R31 was reversible,
because cells that were preexposed to GIV3727 responded
fully to the agonist upon washout of the antagonist (see
Figure S1A available online). Furthermore, we found that
GIV3727 similarly inhibited hTAS2R43 (see Figure S1B), which
is 88% identical to hTAS2R31 and can also be activated by
saccharin and acesulfame K [5], suggesting that this com-
pound would be of interest for further study as a putative bitter
taste inhibitor. The structural identity and purity of the original
sample of GIV3727 (Figure 1C) were confirmed by gas chroma-
tography-mass spectrometry. GIV3727 was resynthesized,
and hTAS2R31 inhibition by the new batch was confirmed
before proceeding with further experiments.
Given the structural dissimilarity between the antagonist
and known agonists (Figure 1C), we examined whether
GIV3727 was acting as a competitive or noncompetitive recep-
tor antagonist. Concentration curves of hTAS2R31 agonists
were constructed in the presence of fixed concentrations of
the inhibitor. Increasing concentrations of GIV3727 resulted
in a rightward shift of the dose-response curves for all three
cognate bitter agonists (Figure 2), suggesting that it might
act at an orthosteric position and competitively inhibit receptor
activation [6, 7]. However, agonist efficacy was also dimin-
ished by GIV3727, as evidenced by the lower maximal signal
amplitudes (Figure 2A), which is typically indicative of allo-
steric antagonism or insurmountable inhibition [6, 7]. We
observed that the EC50 increased 3- to 10-fold for all three
agonists, whereas the signal amplitude decreased by 35%–
70% upon inclusion of 25 mM GIV3727 (Figure 2), and we
conclude that GIV3727 is likely an orthosteric, insurmountable
bitter receptor antagonist [6, 7].
GIV3727 Inhibits Multiple hTAS2Rs
Because GIV3727 inhibited both hTAS2R31 and hTAS2R43,
we were interested to determine whether it can inhibit other
bitter receptors. Therefore, we examined the effects of 25 mM
GIV3727 via calcium imaging by using a panel of transfected
hTAS2Rs with known bitter agonists (18 of the 25 hTAS2Rs).
The receptors and the corresponding bitter agonists [8] tested
are shown in Table 1 along with the effects of GIV3727
on receptor activation. When possible, we utilized an EC90
concentration of bitter agonist, with the exception of four
hTAS2Rs. The low potency and the limited number of available
agonists for these four receptors (hTAS2R3, 5, 7, and 13) did
not allow for an accurate EC90 value to be determined prior
to testing of GIV3727. Therefore, we used the maximal concen-
tration of agonists that activated the receptor without eliciting
Figure 1. Inhibition of hTAS2R31 by GIV3727
(A) Representative FLIPR responses of cells expressing
hTAS2R31, following stimulation with 500 mM sodium sac-
charin in the absence (black trace) or presence (gray trace)
of 25 mM GIV3727. Arrows indicate agonist application, and
the data were corrected for and normalized to background
fluorescence. Calibration: horizontal bar, 100 s; vertical bar,
DF/F = 0.2.
(B) Dose-response profile of hTAS2R31-expressing cells
stimulated with either 500 mM sodium saccharin (d) or
800 mM acesulfame K (C) in the presence of increasing
concentrations of GIV3727. Data are presented as the
mean 6 standard error of the mean (SEM) of at least three
separate experiments performed in duplicate and were fitted
in GraphPad Prism via a 4-parameter logistic fit equation.
(C) Chemical structures of compounds used in this study.
See also Figures S1 and S3.
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could significantly inhibit a total of six bitter taste receptors
(hTAS2R4, 7, 31, 40, 43, and 49) among those tested (Table 1),Figure 2. GIV3727 Is an Insurmountable Antagonist of hTAS2R31
(A) Dose-response curves for acesulfame K, sodium saccharin, and aristolochic acid were pre
activation of hTAS2R31-expressing cells were assessed via calcium imaging in the FLIPR. Dat
experiments performed in quadruplicate and fitted in GraphPad Prism via a 4-parameter logi
(B) Average EC50 values obtained for acesulfame K, saccharin, and aristolochic acid, in the ab
experiment used to generate the data in (A). There was a significant effect (p < 0.0001) of antag
analysis of variance (ANOVA). Post hoc tests (Bonferroni) showed that all three concentrations
activation across all concentrations of agonist.and four receptors exhibited dose-dependent
inhibition by GIV3727 with varying potencies
(Figure S2A). hTAS2R7 was among the receptors
inhibited by GIV3727, but it is not clear whether
inhibition occurs at an equivalent EC90 concen-
tration of agonists because of the low potency of
the bitter agonist. Inhibition was reversible in
hTAS2R40 and hTAS2R43, similar to hTAS2R31
(Figure S2B). Finally, we did not observe inhibition
of the remaining hTAS2Rs by the antagonist.
Together, these studies suggest that GIV3727
acts selectively in a subset of hTAS2Rs.
Inhibition of several hTAS2Rs by GIV3727 was
somewhat surprising given the low sequencehomology in this receptor family. Overall homology among
the hTAS2Rs is only 30%–70% [1], and we initially expected
that the antagonist might interact with only hTAS2R31 andpared, and the effects of 6, 12, or 25 mM GIV3727 on agonist
a are presented as the mean6 SEM of at least three separate
stic fit equation.
sence or presence of GIV3727, which were derived from each
onist concentration on each agonist, as assessed by two-way
of the antagonist significantly (p < 0.0001) reduced receptor
Table 1. Inhibition of Multiple hTAS2Rs by GIV3727
Receptor Bitter Agonist
Percent
Activation in
Presence of
GIV3727 p Value
hTAS2R1 30 mM trans-isohumulone 114.3% 6 6.2% 0.2268
hTAS2R3 3 mM chloroquine 76.7% 6 21.5% 0.2762
hTAS2R4 10 mM colchicine 45.8% 6 17.4% 0.0067
hTAS2R5 300 mM phenanthrolin 100.2% 6 56.9% 0.9954
hTAS2R7 10 mM cromolyn 47.8% 6 17.0% 0.0004
hTAS2R8 100 mM chloramphenicol 95.7% 6 30.6% 0.8422
hTAS2R10 100 mM strychnine 93.9% 6 16.4% 0.4598
hTAS2R13 3 mM denatonium
benzoate
97.5% 6 15.1% 0.7814
hTAS2R14 3 mM aristolochic acid 94.3% 6 14.8% 0.618
hTAS2R16 10 mM salicin 101.1% 6 13.5% 0.8977
hTAS2R20 100 mM cromolyn 62.9% 6 31.8% 0.034
hTAS2R31 3 mM aristolochic acid 61.9% 6 9.3% 0.0013
hTAS2R38 10 mM PTC 104.0% 6 14.6% 0.5599
hTAS2R39 100 mM EGCG 93.7% 6 12.8% 0.6043
hTAS2R40 0.3 mM cohumulone 3.2% 6 6.5% 9.1 3 1026
hTAS2R43 0.3 mM aristolochic acid 2.5% 6 4.9% 1.4 3 1027
hTAS2R46 3 mM strychnine 92.6% 6 8.9% 0.1571
hTAS2R50 300 mM andrographolide 119.0% 6 14.2% 0.0263
Data are presented as the mean6 SEM of n = 3 experiments and have been
expressed as a percent of the signal obtained with an agonist in the absence
of an inhibitor. Statistical significance was assessed by Student’s t test, and
p < 0.05 is considered statistically significant. The following abbreviations
are used: phenythiocarbamide, PTC; epigallocatechin gallate, EGCG. See
also Figure S2.
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lates several receptors seems to parallel emerging trends
for bitter receptor agonists. For example, aristolochic acid
actually activates three different bitter receptors: hTAS2R14,
hTAS2R31, and hTAS2R43 [5, 9]. Similarly, we found that
chlorpheniramine activates eight different hTAS2Rs, whereas
diphenidol appears to activate 15 hTAS2Rs [8]. This
suggests that antagonists, like agonists, have the capacity
to interact with several bitter receptors, which raises inter-
esting questions regarding possible mechanisms. One
possible interpretation is that the three-dimensional architec-
ture is still maintained among the hTAS2Rs despite the low
sequence homology and that GIV3727 is capable of binding
to multiple receptors. An alternate explanation is that
GIV3727 is disrupting G protein coupling, which could also
explain inhibition of several relatively unrelated receptors.
However, a majority of receptors were not inhibited by
GIV3727 despite signaling through the same chimeric G
protein (Table 1), suggesting that inhibition of agonist-
evoked signaling is specific to the hTAS2R subset. It will
be of interest to determine whether the promiscuous activity
of GIV3727 is a property shared by other chemical classes of
bitter receptor antagonists.
Molecular Determinants of Antagonist Binding
Because GIV3727 inhibited several hTAS2Rs, it was of interest
to identify key residues for recognition of this compound in
the targeted receptors, hTAS2R31 and hTAS2R43. Such infor-
mation could be useful for improving potency and selectivity of
this antagonist series. During previous studies in our labora-
tory examining agonist specificity of the hTAS2Rs, we identi-
fied residues important for activation of the bitter taste recep-
tors hTAS2R31, 43, and 46 [10]. We focused on these
receptors because they are closely related and possess highlydistinct agonist activation patterns and because the relatively
few amino acid sequence differences should account for the
pronounced differences in bitter agonist selectivities. The
most obvious amino acid differences between these receptors
are in transmembrane helix 7, where hTAS2R46 contains an
acidic Glu265 and a hydrophobic Ala268, whereas hTAS2R31
and hTAS2R43 both contain basic residues instead (Lys265
and Arg268). Point mutagenesis of the corresponding positions
in all three receptors revealed that agonist activation and
receptor selectivity are largely determined by these two resi-
dues [10]. During the course of the current study, we con-
structed homology models for hTAS2R31 and hTAS2R43
with the crystal structure reported for the b-adrenergic
receptor [11, 12] to examine these receptors for residues
that may interact with GIV3727. Chemical optimization to
improve potency of this scaffold indicated that the -COOH
moiety is essential for antagonist activity because replace-
ment of this group with an ester or corresponding alcohol abol-
ished activity (Figure S3). Therefore, we focused on possible
key interaction sites for this moiety in the homology models.
Docking of GIV3727 in the putative binding pocket indicated
that Lys265 and Arg268 were also likely interaction sites for
the -COOH group of the antagonist (Figure 3A). In Balles-
teros-Weinstein nomenclature [13], these residues occupy
positions 7.39 and 7.42, respectively, and have been previ-
ously shown to participate in ligand binding in other G
protein-coupled receptors (GPCRs) [14–19]. Taken together,
we reasoned that interaction of GIV3727 may also depend on
the same two residues that we previously found to be impor-
tant for agonist selectivity and activation.
To address this question, we tested the existing mutants from
our prior agonist specificity studies for sensitivity to GIV3727.
Consistent with our hypothesis, GIV3727 was more active in
receptors harboring basic residues (native hTAS2R43 or
hTAS2R46E265K/A268R), whereas introduction of the hTAS2R46-
specific residues (E265, A268) into hTAS2R43 abolished activ-
ity (Figure 3B). Our data indicate that these two residues in
helix 7 are important for antagonist activity in hTAS2R31 and
hTAS2R43 and are consistent with the molecular modeling
predictions. This also suggests that GIV3727 is likely binding
in proximity to bitter agonists, because these same two resi-
dues also affect agonist specificity [10]. For example, introduc-
tion of K265 and R268 into hTAS2R46 confers sensitivity
to aristolochic acid, which activates hTAS2R43 but is
inactive in the native hTAS2R46 (Figure S4). Conversely, the
hTAS2R43K265E/R268A mutant can be activated by the hTAS2R46
agonist strychnine, whereas the native hTAS2R43 is insensitive
to this compound (Figure S4). Thus, these residues appear to be
important for both agonist and antagonist activity. The impor-
tance of helix 7 in agonist and antagonist binding has been
observed for other GPCRs, including hTAS1R3, a component
of the sweet and umami taste receptor heterodimers [15, 20].
Elucidation of other residues within hTAS2R31 and hTAS2R43
should further define the degree of overlap between the agonist
and antagonist binding sites.
To determine the individual contributions of each residue,
we generated mutants of hTAS2R46 in which Lys265 or
Arg268 were introduced individually and examined them for
sensitivity to GIV3727. We found that introduction of Lys265
into hTAS2R46 was sufficient to confer sensitivity to the antag-
onist that was indistinguishable from the double mutant,
whereas we did not observe inhibition in the A268R single
mutant (Figure 3C). We also did not observe inhibition by
GIV3727 in other hTAS2R46 mutants harboring nonbasic
Figure 3. Residues in Helix 7 of hTAS2R31 and hTAS2R43
Are Important for Antagonist Activity
(A) Three-dimensional view of the hTAS2R31 domain-
binding pocket for GIV3727 showing the interaction of the
antagonist with Lys265/Arg268.
(B) Site-directed mutagenesis of hTAS2R43 and hTAS2R46
reveals that Lys265/Arg268 are important contact sites for
GIV3727. Receptors werestimulated with a fixed agonist in the
absence or presenceof increasingconcentrations ofGIV3727.
The following agonists and concentrations were used:
hTAS2R43, 0.3 mM aristolochic acid; hTAS2R43K265E/R268A,
10 mM strychnine; hTAS2R46, 3 mM strychnine; hTAS2-
R46E265K/A268R, 1 mM aristolochic acid. For each dose-
response curve, n = 2–3. The data are normalized in percent
to the maximal signal obtained with the agonist in the absence
of the inhibitor and were fitted in GraphPad Prism via a
4-parameter logistic fit equation.
(C) Site-directed mutagenesis of hTAS2R46 reveals that
Lys265 is sufficient for activity of GIV3727. Receptors were
stimulated with an EC90 concentration of agonist in the
absence (black bars) or presence (red bars) of 25 mM
GIV3727. The data are normalized in percent to the maximal
signal obtained with the agonist in the absence of the inhib-
itor. The specific ligands and concentrations used for each
construct can be found in the Supplemental Experimental
Procedures. For each mutant receptor, n = 2–3 experiments
were conducted. **p < 0.005 is considered statistically signif-
icant, Student’s t test. See also Figure S4.
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(Figure 3C). Together, these results suggest that a basic
residue at position 7.39 is a key contact point for GIV3727, at
least within the mutated hTAS2R46 backbone. However,
because the GIV3727 is active in other hTAS2Rs lacking these
two basic residues, we do not rule out the existence of other
residues in determining antagonist binding or specificity for
other hTAS2Rs. Furthermore, presence of a lysine in this posi-
tion is not sufficient to confer sensitivity to GIV3727 in other
hTAS2Rs, because hTAS2R50 also has a lysine at this site
but is insensitive to the antagonist. This implies that residues
from other helices or extracellular loops are more likely to
determine sensitivity to GIV3727 in receptors other than
hTAS2R31 and hTAS2R43.
GIV3727 Decreases Bitter Taste Intensity in Humans
Acesulfame K and saccharin, to a lesser extent, are commonly
used as sugar substitutes for low-calorie food products, and
their acceptance could be significantly increased by blocking
the undesirable bitter tastes associated with them [21]. There-
fore, we wanted to determine whether GIV3727 could reduce
the bitter taste of acesulfame K in vivo via structured human
taste trials. We employed a two-alternative forced-choice
paradigm (2-AFC) [22] coupled with anchored taste intensity
ratings in order to quantify the reduction in bitterness.
Subjects were presented with two aqueous solutions inrandom order: a 2 mM acesulfame K control solu-
tion and the same acesulfame K solution contain-
ing 30 ppm (150 mM) of GIV3727. Panelists were
asked to identify the solution that had the stron-
gest bitter aftertaste and were then instructed to
rate the bitter taste intensity of the solutions with
an anchored line scale. In a separate experiment
with the same cohort, subjects identified the
sweetest solution and then rated the sweet taste
intensity. We found that nearly all of the panelists(95% of cohort) selected the GIV3727 solution as the least
bitter, indicating that inclusion of GIV3727 led to a significant
(p < 0.001) and perceivable decrease in the bitter taste associ-
ated with acesulfame K (Figure 4A). Furthermore, taste inten-
sity ratings of the solutions revealed that GIV3727 significantly
(p < 0.001) decreased the bitterness associated with acesul-
fame K from moderate to merely recognizable (Figure 4A).
In contrast to the effects on bitter perception, GIV3727 had
no effect on the perceived sweetness of acesulfame K,
because only 55% of the panelists selected the control solu-
tion as more sweet (Figure 4B). Similarly, the perceived sweet
intensity ratings obtained for the two solutions were not signif-
icantly different (Figure 4B). The lack of an effect on sweet
taste perception was further confirmed in 2-AFC studies with
sucrose, in which the sample containing GIV3727 could not
be discriminated from the 7% sucrose reference (Figure 4C),
further confirming that GIV3727 specifically affects only bitter
taste perception. Furthermore, we found that GIV3727 has
no discernable taste or aroma of its own, because an aqueous
solution containing 30 ppm GIV3727 could not be discrimi-
nated from a water reference in a triangle test (n = 50, p =
0.196) [22]. Finally, similar results were also obtained in
2-AFC studies, with 3 mM saccharin as the taste stimulus, in
which the reference was also identified as more bitter than
the saccharin solution containing GIV3727 (Figure 4D).
Together, our findings indicate that GIV3727 effectively
Figure 4. Bitter Taste Perception Is Decreased by GIV3727
(A and B) The effects of GIV3727 on the bitterness (A) or sweetness (B) of 2 mM acesulfame K were determined by a two-alternative forced-choice paradigm
(2-AFC) paired with anchored intensity ratings. Panelists were presented with sweetener alone or plus 30 ppm GIV3727 in random order and were asked to
select the solution that was most bitter (A) or most sweet (B). The data on the left of each graph are the fraction of panelists (out of 22 total) that chose a given
solution as the most bitter or sweet. We found that nearly all of the panelists (95% of cohort) selected the GIV3727 solution as less bitter, but they were unable
to detect any effect on sweetness (55% [control] versus 45% [+GIV3727]). The data on the right of each graph show the effects of 30 ppm GIV3727 on the
perceived bitter and sweet taste intensities, which were generated with a 0–100 line scale with anchors at the following points: 0 = no bitterness, 25 = recog-
nizable, 50 = moderate, 75 = strong, 100 = extreme. The taste intensity data are plotted as the mean 6 SEM, and ANOVA was used to assess differences
(samples and judges as main effects). We found that sample intensity ratings for bitterness were significantly different (F1,21 = 83.0; p < 0.001), but there was
no effect on perceived sweet taste intensity of the GIV3727 solution (F1,21 = 0.10; p = 0.754).
(C) Lack of an effect of GIV3727 on sweet taste of sucrose, as assessed via the 2-AFC method. Thirty panelists were presented with 7% sucrose
alone or plus 36 ppm GIV3727 in random order and were asked to select the solution that was most sweet. Data are presented as the fraction of panel-
ists that chose a given solution as the most sweet. Inclusion of GIV3727 had no significant effect on sweet taste perception of the sucrose solution
(p = 0.856).
(D) Effects of GIV3727 on bitterness of saccharin, as determined by 2-AFC. Statistical significance is indicated above the bar and was determined by
a beta-binomial analysis.
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sweeteners.
It is notable that although GIV3727 abolished hTAS2R31
and hTAS2R43 receptor activation in vitro (Figure 1), not all
panelists detected a complete reduction in bitterness in vivo
(Figure 4A). The taste intensity ratings revealed that GIV3727
reduced the bitterness of acesulfame K from moderate to
recognizable, so it did not fully abolish the bitterness. Several
factors may contribute to this apparent discrepancy between
in vitro and in vivo results. In cell-based assays, receptor
access is relatively unimpeded because the cells are bathed
in the solution containing the antagonist. In contrast, anatom-
ical constraints in vivo may limit compound access, lead-
ing to reduced efficacy. Single-nucleotide polymorphisms
(SNPs) that affect bitter agonist activity in vitro and in vivo
have been identified in the hTAS2R gene family [23–25]. It is
possible that nonsynonymous SNPs or even genomic dele-
tions within the hTAS2R31 and hTAS2R43 genes could
diminish the effects of GIV3727 in a small number of individ-
uals. Finally, the artificial sweeteners used in the current study
elicit both sweet and bitter sensations, which may hinder
discrimination between different taste solutions or taste attri-
butes [26]. Nevertheless, our studies revealed that GIV3727
has efficacy in vivo in reducing the bitterness associatedwith the sulfonamide sweeteners, consistent with our in vitro
findings.Conclusions
In this paper, we describe the identification and characteriza-
tion of GIV3727, which to our knowledge is the first reported
small molecule bitter taste receptor antagonist with in vivo effi-
cacy. Although lactisole or 2-(4-methoxyphenoxy)-propanoic
acid is widely known as an inhibitor of the human sweet taste
receptor [15, 27, 28], this is the first antagonist targeting the
hTAS2R bitter receptors. These results are an important step
toward understanding how bitter taste perception and/or
signaling can be modulated via small molecules. Furthermore,
hTAS2R inhibitors could help to determine the contributions of
bitter taste perception during the ingestion of a complex meal.
Moreover, recent evidence indicates that bitter receptors are
also expressed in other nongustatory tissues with proposed
roles in the detection of noxious airborne chemicals [29] or
regulation of glucose homeostasis via the gastrointestinal
tract [30]. Bitter receptor antagonists such as GIV3727 could
potentially be very useful as chemical probes to examine the
precise contributions of bitter receptor signaling in nongusta-
tory systems. Finally, this approach also has the potential to
Discovery of a Novel Bitter Receptor Inhibitor
1109improve the taste profile of packaged foods and beverages
and to improve oral administration of bitter-tasting medicines.
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Supplemental Information includes Supplemental Experimental Proce-
dures, five figures, and one table and can be found with this article online
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